These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21174558)

  • 1. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.
    Van Kaer L; Parekh VV; Wu L
    Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
    Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
    Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iNKT-cell responses to glycolipids.
    Parekh VV; Wilson MT; Van Kaer L
    Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
    Berkers CR; Ovaa H
    Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iNKT cells in microbial immunity: recognition of microbial glycolipids.
    Kinjo Y; Ueno K
    Microbiol Immunol; 2011 Jul; 55(7):472-82. PubMed ID: 21434991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vivo response of invariant natural killer T cells to glycolipid antigens.
    Parekh VV; Lalani S; Van Kaer L
    Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
    Miyake S; Yamamura T
    Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.
    Veerapen N; Kharkwal SS; Jervis P; Bhowruth V; Besra AK; North SJ; Haslam SM; Dell A; Hobrath J; Quaid PJ; Moynihan PJ; Cox LR; Kharkwal H; Zauderer M; Besra GS; Porcelli SA
    Bioconjug Chem; 2018 Sep; 29(9):3161-3173. PubMed ID: 30085659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
    van der Vliet HJ; Molling JW; von Blomberg BM; Nishi N; Kölgen W; van den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
    Clin Immunol; 2004 Jul; 112(1):8-23. PubMed ID: 15207777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.
    Van Kaer L; Wu L
    Front Immunol; 2018; 9():519. PubMed ID: 29593743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
    Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
    Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
    Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
    Front Immunol; 2019; 10():352. PubMed ID: 30881361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant natural killer T cell-based immunotherapy for cancer.
    Motohashi S; Nakayama T
    Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing NKT cell ligands as vaccine adjuvants.
    Carreño LJ; Kharkwal SS; Porcelli SA
    Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
    Florence WC; Bhat RK; Joyce S
    Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
    Gabriel L; Morley BJ; Rogers NJ
    Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.